Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06588946 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Β-OHB Supplementation and Brain Health in Older Adults

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Phase: Not applicable to Phase 2 Primary and study completion dates: Aug 2026 to Aug 2027 · Start date: Nov 2024 to Mar 2025 · Enrollment target: 60 to 48 · 4 morev2 Show 7 more changesShow less
    • Primary and study completion dates: Aug 2026 to Aug 2027
    • Start date: Nov 2024 to Mar 2025
    • Enrollment target: 60 to 48
    • Eligibility criteria shortened, about 11 words
    • Secondary endpoints: 5 to 4
    • Study description shortened, about 1,316 words
    • Study title shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this randomized placebo controlled crossover trial is investigate the effects of short-term ketone monoester (KME) supplementation to brain function in older adults with subjective cognitive decline. We will test the hypothesis that KME supplementation will increase cerebral blood flow and improve resting-state functional connectivity in the brain compared to placebo supplementation in older adults with subjective cognitive decline. Participants will be randomly assigned to either placebo of KME supplementation for 14 days. Following a washout period, participants will complete the alternate condition for 14 days. Outcome measures will be assessed before and after each intervention period.
Trial Details
NCT Number NCT06588946
Lead Sponsor McMaster University
Collaborators: Heart and Stroke Foundation of Canada
Conditions Subjective Cognitive Decline
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov